| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT04368559) | Mundipharma Research Limited | 2020-05-11 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (NCT04148287) | Basilea Pharmaceutica | 2019-12-13 |
| Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood (NCT04147975) | HelixBind, Inc. | 2019-10-01 |
| Echinocandins Versus Azoles for Candidemia Treatment (NCT03799172) | Hospices Civils de Lyon | 2018-11-01 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (NCT03667690) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-10-07 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia (NCT03604705) | Basilea Pharmaceutica | 2018-10-03 |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) (NCT03363841) | Scynexis, Inc. | 2017-11-15 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (NCT02734862) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-07-26 |
| Bio-assay Development and Implementation for Fungal Infection Detection (NCT02333266) | Universitaire Ziekenhuizen KU Leuven | 2016-06-01 |
| Non-Conventional Microbiological Methods in the Diagnosis of Candidemia (NCT07422155) | Institute of Oncology Ljubljana | 2015-01-01 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis (NCT02244606) | Scynexis, Inc. | 2014-09-01 |
| Serial Therapeutic and Antifungal Monitoring Protocol (NCT02163889) | T2 Biosystems | 2014-09-01 |
| A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (NCT01982071) | Astellas Pharma China, Inc. | 2013-09-26 |
| Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study) (NCT01752166) | T2 Biosystems | 2013-07-01 |
| Genetic Susceptibility Factors for Candidemia. (NCT02841501) | University Hospital, Lille | 2013-06-01 |
| Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV (NCT00802854) | Pfizer | 2012-03-02 |
| Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT) (NCT01525095) | T2 Biosystems | 2012-01-01 |
| Risk Factor and Outcome of Candidemia (NCT01249313) | China Medical University Hospital | 2011-09-01 |
| Anidulafungin Pharmacokinetics in Intensive Care Unit Patients (NCT01438216) | Amsterdam UMC, location VUmc | 2011-09-01 |
| Early- and Late-onset Candidemia (NCT01406093) | Giovanni Di Perri | 2011-05-01 |
| SIHAM Candidemia Network:An Observational Study (NCT01281345) | Society of Indian Human & Animal Mycologist | 2011-04-01 |
| Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia (NCT01270490) | Radboud University Medical Center | 2011-01-01 |
| A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis (NCT01176058) | Pfizer | 2010-12-01 |
| A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093) (NCT01174147) | Merck Sharp & Dohme LLC | 2010-04-01 |
| UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients (NCT01622595) | University of Arkansas | 2009-11-01 |
| Prevalence and Epidemiology of Nosocomial Candidaemia and Antifungal Susceptibility Patterns in an Italian Tertiary-Care Hospital (NCT00903526) | University of Modena and Reggio Emilia | 2009-03-01 |
| Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins (NCT00839540) | Gary E. Stein, Pharm.D. | 2008-12-01 |
| Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection (NCT00739934) | Pfizer | 2008-12-01 |
| A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects (NCT00940017) | Pfizer | 2008-09-01 |
| Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins (NCT01213823) | Pfizer | 2008-09-01 |
| This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis (NCT00548262) | Pfizer | 2008-02-01 |
| Anidulafungin In Treatment Of Candidemia In Asian Subjects (NCT00537329) | Pfizer | 2008-01-01 |
| Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug (NCT00608335) | Astellas Pharma Inc | 2007-10-14 |
| Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug (NCT00607763) | Astellas Pharma Inc | 2007-10-01 |
| Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections (NCT00413218) | Astellas Pharma Inc | 2007-03-08 |
| Study of Micafungin in Patients With Invasive Candidiasis or Candidemia (NCT00105144) | Astellas Pharma Inc | 2004-09-01 |
| Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia (NCT00189709) | Astellas Pharma Inc | 2004-08-01 |
| Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants (NCT00113191) | Bristol-Myers Squibb | 2004-05-01 |
| Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal (NCT02088476) | Hacettepe University | 2004-01-01 |